Bristol-myers Squibb Compnay

Pavan Kalyan Kathi

Dean A Wacker

Susheel Jethanand Nara

Srinivas Cheruku

Kandhasamy Sarkunam

Soodamani Thangavel

Firoz Ali Jaipuri

Srinivas Jogi

Rishikesh Narayan

Subba Reddy Bandreddy

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, when Q is: (i) halo, cyano, hydroxyl, NRR, C(O)OH, C(O)NH, Calkyl substituted with zero to 6 R, or P(O)RR, or (ii) L R; and A, X, X, X, X, Z, Z, R, R, R, R, R, R, R, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Substituted amide compounds useful as farnesoid X receptor modulators

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R; and A, X, X, X, X, Z, Z, R, R, R, R, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Substituted bicyclic compounds as farnesoid X receptor modulators

Growing community of inventors

Bengaluru, India

Pavan Kalyan Kathi